A 35 year’s old male presented with right testicular swelling for last six month. He developed hemoptysis and mild dyspnea for 2 weeks. Ultrasonography revealed testicular malignancy with multiple heterogenecity. CT scan of the abdomen did not reveal any lymph node metastasis. His X-ray chest showed extensive pulmonary metastasis. All three tumor markers were raised. Histology was suggestive of mixed germ cell tumor with a rare combination of Seminoma and Choriocarcinoma. Because of this rare combination of 2 varieties of testicular germ cell tumor and advanced systemic metastasis we presented this case.

Primary testicular tumors are the most common solid malignant tumor in men between the ages of 20 and 35 years. For unknown reasons, the incidence of this cancer has increased during the last century. Most testicular tumors are derived from the germ cells of the testis, although about 5% of testicular tumors are derived from other cells, including Leydig cells and lymphocytes (lymphoma).
The cause of testicular tumors is unknown, but several predisposing factors are recognized. Cryptorchidism, genetic susceptibility, family history, and past history of testis cancer have been reported as the important risk factors. Their incidence has increased over the past century. Ninety-five percent of testis tumors originate from germ cells while the remaining 5% are Leydig cell tumors and lymphomas (1). Germ cell tumors can be broadly classified as seminomatous and non-seminomatous. Approximately 60% of germ cell tumors are mixed germ cell tumors (2). Painless swelling or nodule in testis is usually the most common symptom. However, metastasis-related symptoms may be the first presenting symptom (3). We report a patient diagnosed with mixed germ cell tumor presenting with hemoptysis and mild dyspnea due to massive lung metastasis.

Any solid, firm mass within the testis should be considered testicular cancer until proven otherwise. Prompt diagnosis and early treatment are required for cure. Testicular cancer may be painless, in which case they are sometimes ignored by the patient. In patients with scrotal pain, testicular cancer must be differentiated from epididymo-orchitis. The clinician should consider the full differential diagnosis of a testicular mass, which includes epididymo-orchitis, testicular torsion, hydrocele, hernia, hematoma, spermatocele, varicocele, and syphilitic gumma.
In the past, metastatic testicular cancer was usually fatal, but recent advances in treatment, including high-dose chemotherapy and stem cell rescue, have considerably improved the prognosis. Indeed, testicular cancer is a bright spot in the oncological landscape and are now considered to be the model for treatment of solid tumors.

A 35 years old male presented with six month history of painless swelling of the right testis. He ignored this swelling. He developed hemoptysis and mild dyspnea for two weeks. He did not complain of any abdominal pain. On examination his right testis was swollen, firm to hard in consistency and having smooth surface. It was oval in shape but size was about 8cm/5 cm    (Fig-1). The testis was not fixed with the scrotal wall. Ultrasonography showed a right testicular mass with multiple heterogenecity. There was no fluid collection in the scrotum. CT scan of the abdomen did not reveal any lymph node enlargement. His chest x-ray showed an extensive multiple cannon ball appearance on both lung fields (Fig-2). His serum marker was done. His α-feto protein was >1000 U/ml (range0.5-5U/ml) ß-HCG was 399U/L (normal<10>

Non-seminomatous germ cell tumors are highly aggressive malignancies of the testis. Histologically, approximately 70% of the non-seminomatous germ cell tumors are composed of more than one germ cell component, which is called mixed germ cell tumor. Several studies have reported specific combinations of different elements in mixed GCT of testis [4, 5]. Mostofi [5] in classifying more than 6000 testicular tumors found >1 histological patterns in approximately 60% of cases with the most frequent combination of embryonal carcinoma, yolk sac tumor and choriocarcinoma. Statistical analysis of possible combinations by Mosharafa et al. revealed 10 possible pair combinations. Complete diagnosis requires obtaining an appropriate specimen for making the correct diagnosis together with the correlation of the serum tumor markers. This is important for staging and also for postoperative follow up and to know the response of the treatment and surveillance. α-fetoprotein (AFP) is produced by the yolk sac elements and is elevated in 50-70% of NSGCT. It is not usually elevated in pure seminoma. Its half-life is about 5 days. β-human chorionic gonadotrophin (β-HCG) is produced by trophoblastic elements in the tumor. It is raised in 40 to 60% of NSGCTs and in up to 30% of pure seminomas. It has a half-life of 1 day. Lactate dehydrogenase (LDH) is less specific, but is more common in seminoma. Overall, 90% of NSGCTs elaborate at least one tumor marker, while markers are elevated in <40>

Choriocarcinoma is relatively rare among the various components of non-seminomatous germ cell tumors, including embryonal carcinoma, seminoma, yolk sac tumor and teratoma. Less than 8% of the testicular germ cell tumors contain a choriocarcinoma component, and pure choriocarcinoma accounts for only 0.3% of all the primary testicular germ cell tumors [6].

The term choriocarcinoma is generally used to refer to gestational choriocarcinoma, which most commonly occurs with hydatidiform mole. It is a cancer that typically occurs in the chorionic epithelium of the placenta of females and it rarely occurs in males. Choriocarcinoma in the testis has a particularly high-risk histology and the patients with this tumor are prone to present with metastases rather than a testicular mass. The most common presenting symptoms include hemoptysis secondary to pulmonary metastases, back pain secondary to retroperitoneal spread, gastrointestinal bleeding due to gastrointestinal tract metastases and neurological symptoms that are due to brain metastases [7].

Yokoi K et al. recently reported a review of the literature on choriocarcinoma [6]. They examined the characteristics of this tumor based on 106 cases of male choriocarcinoma that were reported during the previous 12 years (1995 to 2005). The testis was the most common primary site at 33% (35/106), followed by the mediastinum, pineal body, gastrointestinal tract, lung and retroperitoneum. Metastasis was seen in 83% of the patients, with multiple metastases seen in most of the patients. The most common metastatic sites were the lung, liver and brain. The mean age of the males with choriocarcinoma was 36.0 years, and this tumor tended to occur in children and adolescent, where the age of two thirds of all the cases (69/106) was less than 30-years old. The prognosis of male choriocarcinoma was very poor, with the cumulative survival rate being 30%, and the course of the disease was rapid with the mean survival time being 7.7 months; 23.8% and 45.4% of the patients showed 1-month and 6-month mortality, respectively [6].

Patients with advanced choricocarcinoma have a worse prognosis than do the patients with other advanced/poor prognosis non-seminomatous GCTs because of the very high levels of hCG and the propensity for pulmonary and non-pulmonary visceral metastases [8]. Jensen and Venner [9] presented data from a population of 77 advanced germ cell patients who were treated with cisplatin-based therapy, and 3 of 77 patients had pure choriocarcinoma. All the three patients with pure choriocarcinoma died. The recurrent pure choriocarcinoma also has a very poor prognosis. There has been a report on a large series from Indiana University of 135 patients with GCTs and these patients failed after the first-line, platinum-based therapy, and the patients were treated with standard salvage chemotherapy with vinblastine, ifosfamide and cisplatin. Thirty-two patients were long-term survivors, but all the seven choriocarcinoma syndrome patients died . However, Papiani and Einhorn [9] reported that long-term survival and a potential cure was possible with high-dose chemotherapy in the patients with recurrent choriocarcinoma. The patients with choriocarcinoma who fail to achieve a complete response (CR) to the first-line therapy (the so-called incomplete responders) have a less than a 10% likelihood of long-term survival with the second-line chemotherapy [10,12]. We could not follow up the patient regarding response to the chemotherapy as he was transferred to a cancer institute for further treatment.